Upstate Active Clinical Trials

Study Title:

2215-CL-0302: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of FLT3 Inhibitor Gileritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission

Upstate Institutional Review Board (IRB) Number:

976763

Study/Protocol ID:

2215-CL-302

Patient Age Group:

Adults

Principal Investigator:

Teresa C Gentile, MD, PhD

Who can I contact for more information?

Name: Deanna J Cogswell, LPN
Phone: 315-464-8237
Email: cogsweld@upstate.edu

Return to Previous Page || Search Again